(NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the ...

NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading ...

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), and NeoGenomics Laboratories, Inc., a leading provider of ...

Lab is located in same building as PPD® Laboratories’ Central Lab and will support Asia-Pacific oncology trials Fully integrated with PPD’s CRO capabilities, PPD Laboratories offers bioanalytical, ...

FT. MYERS, Fla., Oct. 23, 2018 (GLOBE NEWSWIRE) — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive ...

Pharmaceutical Product Development and NeoGenomics Laboratories plan to integrate their international pathology and molecular testing offerings, with NeoGenomics providing lab services for PPD’s ...

Fort Myers-based NeoGenomics Inc. is growing again. The company, specializing in genetic testing for cancer, announced it has completed the acquisition of Genoptix Inc., a leading clinical oncology ...

NeoGenomics (NASDAQ:NEO) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement. Analysts estimate that NeoGenomics will ...

The company has a new CEO, Chris Smith, who took over in July. NeoGenomics reported a 6% rise in revenue year over year. The company seems to be benefitting from a post-pandemic environment. The ...

This time it's going to China. The Fort Myers-based laboratory — specializing in genetic testing for cancer — has announced plans to grow its global footprint with the addition of a research lab in ...

Despite experiencing a double-digit decline in test volumes, the cancer genetics lab hasn't furloughed employees. It has even retooled labs to process COVID-19 swab and blood tests. The slowdown is ...

In its quest for growth, NeoGenomics has found its next target for acquisition. The Fort Myers-based company, specializing in genetic testing for cancer, has signed a definitive agreement to acquire ...